ROBERT BUTORA

Issues related to patient access to home medical equipment and related reimbursement.

Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.

FY 2027 Appropriations.

Specific issues "monitoring and reporting on reconciliation legislation"; implementation of PL 119-21.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices. CMS RAPID Proposed Rule.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Issues related to TrumpRX.

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. Issues related to China WRT the BINSA bill.

Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). Implementation of MCED, CMS RAPID proposed rule, and VA coverage of multi cancer tests.

Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to most favored nation pricing polices.

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX. Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267).

Drug importation, prescription drug safety, value and access.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. Issues related to China WRT the BINSA bill.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Issues related to TrumpRX.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

General cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research. Clinical Trial Modernization Act (HR 3521/S.4440).

Implementation of Medicare Multi-Cancer Early Detection Screening Coverage Act.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Issues related to China WRT the BINSA bill.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Issues related to TrumpRX.

Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.

Issues related to health insurance and affordability.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

General education about estradiol patch supply and demand issues and discussions on FDA shortage evaluations.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues.

Issues related to provisions in the annual appropriations process that regulate Hemp.

Issues related to regulation of Hemp products. H.R. 7024, Hemp Planting Predictability Act.

HR 7212 To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of cannabinoid hemp products, and for other purposes. H.R.9830 - Lawful Hemp Protection Act.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Advocate on the regulatory environment regarding pediatric therapy services, including rulemakings at Health and Human Services.

Advocate on the regulatory environment regarding pediatric therapy services, including rulemakings at Health and Human Services.

Work to resolve supply shortage issues with female hormone patch.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Support for obesity drug coverage and access.

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794).

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.

FY 2027 Appropriations.

Specific issues "monitoring and reporting on reconciliation legislation"; implementation of PL 119-21.

Issues related to patient access to home medical equipment and related reimbursement.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.

Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues.

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). HR 1, One Big Beautiful Bill Act.

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794).

Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

General cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research. Clinical Trial Modernization Act (HR 3521/S.4440).

Medicare Multi-Cancer Early Detection Screening Coverage Act.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.

HR 7212 To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of cannabinoid hemp products, and for other purposes.

Issues related to provisions in the annual appropriations process that regulate Hemp.

Issues related to regulation of Hemp products. H.R. 7024, Hemp Planting Predictability Act.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.

Issues related to health insurance and affordability.

Advocacy on Department of Veterans Affairs health care policy and administration of the Community Care Network.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Animal health, issues impacting medicines and vaccines for animals.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

Support for obesity drug coverage and access.

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

FY 2027 Appropriations.

Issues related to access to home medical equipment and related reimbursement (i.e., the "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4307) and the "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, the "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels. Issues related to continuous glucose monitors.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.

Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues.

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). HR 1, One Big Beautiful Bill Act.

Drug importation, prescription drug safety, value and access.

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

General cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research.

Medicare Multi-Cancer Early Detection Screening Coverage Act.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.

Issues related to provisions in the annual appropriations process that regulate Hemp.

Issues related to regulation of Hemp products. H.R. 7024, Hemp Planting Predictability Act.

HR 7212 To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of cannabinoid hemp products, and for other purposes.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to Advance Premium Tax Credits (APTCs) and cost-sharing reductions.

Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.

Advocacy on Department of Veterans Affairs health care policy and administration of the Community Care Network.

Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

Providing strategic counsel on congressional and administrative issues, including drug pricing, Medicare and Medicaid, 340B, tax and trade, intellectual property, and FDA regulatory matters.

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues.

Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.

Animal health, issues impacting medicines and vaccines for animals.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs.

Support for obesity drug coverage and access.

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.

FY26 Appropriations.

Specific issues "monitoring and reporting on reconciliation legislation"; implementation of PL 119-21.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). HR 1, One Big Beautiful Bill Act.

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies.

Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

General access cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research.

Medicare Multi-Cancer Early Detection Screening Coverage Act.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.

Issues related to Advance Premium Tax Credits (APTCs) and cost-sharing reductions.

Advocacy on Department of Veterans Affairs health care policy and administration of the Community Care Network.

Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

Budget, appropriations, veterans, and clinical research.

Assist UVCAs advocacy by executing a legislative strategy and leading discussions with the VA and House/Senate VA committees on how the proposed program changes and reorganization could disrupt the Community Care Network and negatively impact veterans continuity of care.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Animal health, issues impacting medicines and vaccines for animals.

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs.

Support for obesity drug coverage and access.

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.

FY26 Appropriations.

Specific issues "monitoring and reporting on reconciliation legislation" and H.R. 1, One Big Beautiful Bill Act.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). HR 1, One Big Beautiful Bill Act.

Drug importation, prescription drug safety, value and access.

Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

General access cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research.

Medicare Multi-Cancer Early Detection Screening Coverage Act.